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Abstract 
Objective: This study aims to describe the pharmacodynamics (PD) of a fluid 
challenge over a ten-minute period in post-operative patients. 
Design: Prospective observational study 
Setting: General and cardiothoracic intensive care unit, tertiary hospital. 
Patients: 26 post-operative patients.  
Intervention: 250 ml fluid challenge performed over 5 minutes. Data was recorded 
over 10 minutes after the end of fluid infusion 
Measurements and main results: Cardiac output (CO) was measured with a calibrated 
LiDCOplus™ (LiDCO, UK) and Navigator™ (Applied Physiology, Australia) to obtain the 
Pmsf analogue (Pmsa). PD outcomes were modelled using a Bayesian inferential 
approach and Markov chain Monte Carlo estimation methods. Parameter estimates were 
summarized as the means of their posterior distributions and their uncertainty was 
assessed by the 95% Credible Intervals (CrI). Bayesian probabilities for groups’ effect were 
also derived. The predicted maximal effect on CO was observed at 1.2 minutes (95% CrI -
o.6 to 2.8) in responders. The probability that the estimated area under the curve of 
central venous pressure (CVP) was smaller in non-responders was 0.12. (estimated 
difference -4.91 mmHg·min (95% CrI –13.45 to 3.3). After 10 minutes, there is no evidence 
of a difference between groups for any haemodynamic variable. 
Conclusion: The maximal change in CO should be assessed one minute after the end 
of the fluid infusion. The global effect of the fluid challenge on CVP is greater in non-
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responders but not its change ten minutes after the fluid infusion. The effect of a fluid 
challenge on hemodynamics is dissipated in ten minutes similarly in both groups. 
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Introduction 
The administration of intravenous (IV) fluids is essential for the management of 
critically ill patients. In order to reduce any undesirable effects from the inappropriate use 
of fluids (1-4), the fluid challenge technique has been recommended (5, 6) and it is one of 
the commonest interventions in intensive care. A fluid challenge is a test in which a small 
bolus of IV fluid is given over a short period of time to assess haemodynamic response (7) 
and it is considered as the “gold standard” test for assessment of fluid responsiveness (8, 
9). 
Weil and Henning (5) proposed that an increase of CVP greater than 2 cm H2O 
sustained over 10 minutes indicates that no additional fluid should be given. If it declines, 
the fluid challenge should be resumed. As far as we know, this concept has not been 
tested. Moreover, despite the fact that a fluid challenge is a very common practice, there 
is little agreement regarding how to perform it: reviews of the literature show marked 
heterogeneity of triggers, volume infused, time of assessment or variable targets (10, 11). 
Recently, a multicentre international observational study assessed the way a fluid 
challenge is performed and the results highlight the great variability in terms of volume 
used, rate of infusion, timing of the measurements and interpretation of results (12). The 
authors highlight the need of more research in order to standardise this technique. 
Guyton (13) observed that an acute expansion in blood volume increases the mean 
systemic filling pressure (Pmsf) and generates a progressive stretching of the vascular 
system so that, after some minutes, the Pmsf falls back to the baseline level, in a similar 
fashion to CO, despite the expansion of circulating volume (13). Pmsf is the pressure 
generated by the volume within the cardiovascular system under static conditions (no 
blood motion) (14). Pmsf depends on the mean compliance of the cardiovascular system 
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and the intravascular volume and is a key determinant of both venous return (VR) and 
CO. Guyton’s observations suggest that a very rapid stress relaxation occurs in the 
circulatory system following the expansion of intra-vascular volume and, as a 
consequence, the effect of the fluid challenge may be rapidly dissipated. 
The objective of the present study is to describe the pharmacodynamics of a fluid 
challenge across several haemodynamic variables and to explore the differences 
between responders and non-responders in a group of post-operative patients. 
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Material and Methods 
The National Research Ethics Service Committee considered this study a service 
evaluation and it was approved by the institutional Joint Research and Enterprise Office; 
therefore no written informed consent was required. 
This is a prospective observational study performed in the general and cardiothoracic 
intensive care units (ICU), of a tertiary university hospital between November 2011 and 
September 2014. Post-operative patients admitted to the ICU and receiving a fluid 
challenge in accordance with our goal-directed therapy protocol (ESM Appendix 1) (15, 
16) were eligible for this study. Patients without a central venous catheter, known or 
post-operative aortic valve regurgitation, presence of an intra-aortic balloon pump, 
known pregnancy, body weight less than 50 kg, known or suspected sepsis and patients 
in haemorrhagic shock requiring blood products were excluded. In addition, patients with 
perioperative echocardiographic evidence of severe right or left ventricular dysfunction 
and patients who required aggressive fluid resuscitation or changes in sedo-analgesia, 
vasoactive therapy or respiratory support during the period of study were also excluded. 
The study period was not initiated until the haemodynamics were in a steady state - 
defined by changes in mean arterial pressure, heart rate and CO no greater than 10 % 
during 10 minutes before data recording. Patients received one or more fluid challenges 
according to the clinical prescription. 
Cardiovascular monitoring 
Patients had continuous arterial blood pressure monitoring from a radial artery 
catheter (115.090 Vygon, Ecouen, France). CVP was measured with a venous central 
catheter (CV-15854, Arrow International, Reading, USA) inserted into the internal jugular 
or the subclavian vein. Both catheters were connected to a pressure transducer 
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(T001650A, Edwards Lifesciences LLC, Irvine, USA) and to a multi-parameter monitor 
(InfinityTM Delta, Drager Medical Systems, USA). Zero levels for pressure measurements 
were referenced to the intersection of the anterior axillary line and the fifth intercostal 
space.  
CO was measured with the LiDCOTMplus system (17) (LiDCO Ltd, Cambridge, UK) 
calibrated with an injection of lithium chloride (0.3 mmol) given according to the 
manufacturer’s recommendation (18, 19). Beat-to-beat CO and stroke volume (SV) was 
obtained with LiDCOTMplus pulse power analysis(20). 
Determination of Pmsf-analogue: Pmsa 
The Navigator TM software system (Applied Physiology, Sydney, Australia) was 
connected to the multi-parameter monitor and to the LiDCOTMplus. Pmsa calculation is 
based on the values of CO, CVP, mean arterial pressure (MAP), and patient’s 
anthropometric measures (height, weight and age) (21, 22).  
Fluid challenge 
The fluid challenge consisted of 250 ml of crystalloid (Compound sodium lactate, 
Baxter Healthcare Ltd, U.K) infused using a syringe of 50 ml and performing 5 boluses 
over 5 minutes. According to the clinical protocol, an increase in CO immediately after the 
fluid challenge greater than 10% was considered a positive response (R). The values 
recorded at baseline and immediately after the fluid challenge were used for this 
classification.  
Pharmacodynamic analysis 
Haemodynamic values were recorded electronically during the whole study period in 
a log file. The data uploaded from the LiDCOplus™ monitor was set to record at a beat to 
beat basis, and the NavigatorTM monitor recorded a data sample of all variables every 10 
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seconds. The data for analysis were obtained at base line, at the end of the infusion, and 
1, 2, 4, 6, 8, and 10 minutes after the end of fluid infusion.  
Several variables of interest were defined as outcomes to describe the effect of a 
fluid challenge on haemodynamic variables: the global effect over ten minutes can be 
quantified as the net area under the curve (AUC) calculated using the trapezoidal rule 
from the baseline value (23). In addition the maximal difference from baseline observed 
(dmax), maximal value observed (Emax), time when the maximal value was observed (tmax) 
and change from baseline at 10 minutes time (d10) are also reported. 
Statistical analysis 
The data was explored graphically and summarized according to its nature, i.e. 
means, medians, interquartile range (IQR) and standard deviation (SD) for continuous 
variables and percentages for categorical/binary variables. Classical frequentist 
approaches such as Kruskal-Wallis equality-of-population rank test and Fisher’s exact test 
were implemented for independent data (baseline measurements) and results assessed 
through classical p-value with values below 0.05 deemed as statistically significant. Each 
patient is subjected to one or more fluid challenges and that can result in multiple 
measurements per individual. Hence, the data exhibit a hierarchical structure with two 
levels of variability, which need to be accounted for: between subjects as a well as within 
subject variability.  
A random slopes modeling framework allows each individual’s slope (which reflects the 
association between an individual outcome (say AUC Pmsf) with the corresponding 
individual measurements) to vary. The inference consists in estimating an average line 
(defined by an average intercept and an average slope), reflecting the association of the 
outcome with baseline measurements by clinical group (i.e. responders and non-
responders) as well as the average value of the outcome for an average baseline 
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measurement. In other words, we understand the average group behavior accounting for 
individuals’ variability.  
A Bayesian framework for statistical inference and Monte Carlo Markov chains 
(MCMC) methods were implemented. Unlike the frequentist approach, the parameter 
values are random variables rather than numbers and therefore summarized by their 
means and 95% credible intervals (CrI) of their posterior distributions and reported 
accordingly. Unlike the classical 95% confidence intervals, the 95% CrI can be interpreted 
as the 95% chance that the mean belongs within its limits. No prior knowledge was 
assumed for any of the parameters, which included the estimated variances. In order to 
quantify the extent to which the two groups differ with respect to their outcome, the 
probability that the mean outcome in responders is greater (or smaller) than in non-
responders was calculated. We shall refer to this as to the Bayesian probability of the 
group effect to avoid confusion with the classical p-value. The sense of interpretation 
depends on the clinical connotation. Probabilities smaller than 0.05 and greater than o.95 
were considered as strong evidence. Probabilities smaller than 0.21 and greater than 0.79 
were deemed as fairly good evidence.  
Two sets of statistical models of increasing complexity were fitted to data. One set 
labelled as a simple models involves two main parameters of interest: one quantifies the 
difference between responders and non-responders (∆(R – NR)) and the second one the 
average change in outcome for one unit increase in the baseline of each haemodynamic 
variable irrespective the group (R or NR). The other set called interaction models explores 
the possibility that the average changes in outcomes for one unit increase in the baseline 
may differ across the two groups of patients. 
Mean pharmacodynamics outcomes are the predicted after parameter estimation for 
each group, for an average baseline value following inference from the interaction 
Pharmacodynamics of a fluid challenge 10 
models set. The deviance information criterion (DIC) has been employed to assess choose 
between models of different fit – the smaller the value, the better the fit. However, 
model choice has been also subjected to clinical considerations rather than strictly 
following formal statistical rules. 
Statistical software used included OpenBUGS (24, 25), STATA (StataCorp. 2013. Stata 
Statistical Software: Release 13. College Station, TX: StataCorp LP) and R (R Core Team 
(2012). R: A language and environment for statistical computing. R Foundation for 
Statistical Computing, Austria. URL http://www.R-project.org/)
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Results 
50 fluid challenges were observed in 26 patients. Demographic and baseline data is 
presented in Table 1. The median (IQR) number of fluid challenges per individual was 2 (1 
– 2) with 1 (1 – 2) in non-responders and 2 (1 – 3) in responders. 13 (50%) patients were 
responders. The median time between fluid challenges was 27 minutes (18 – 43). In 2 
patients a different response in CO was observed after the initial fluid challenge. From 
the total number of events, 26 (52%) were responders. The median fluid infusion time was 
3.4 (2.6 – 4.1) minutes.  
Baseline and demographic data was not significantly different between groups (Table 
1) except for the ICNARC score, which did not reveal a significant effect (the CrIs 
approximately evenly spread around 0 when model was taking in account ICNARC 
values). The results are presented according to the interaction model although some of 
the results were not statistically superior but physiologically consistent. Results are 
summarised in Tables 2 and 3. For all the variables, an increase in baseline corresponds 
with an increase in the estimated maximal value (Emax). 
Mean arterial pressure 
The estimated global effect of the fluid challenge (AUC) is similar in both groups 
(table 2), however, in responders the maximal effect was achieved faster (1.58 min 
(95%CrI -0.15 to 3.31) vs. 4.5 min (95% CrI 2.7 to 6.3) Probability of ∆(R-NR)>0 = 0.01). The 
higher MAP at baseline, the smaller AUC and d10 in both groups. However, the higher 
MAP at baseline, the smaller is dMax in responders and the shorter the time to reach it. 
(Table 3, Figure 1 and 2). 
Cardiac output 
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In responders the estimated AUC was greater (estimated AUC (R-NR) 1.9 L (95% CrI -
0.7 to 4.5), probability (R-NR)> 0 = 0.93), the maximal effect on CO was greater 
(estimated dmax (R-NR) 0.29 L/min (95% CrI -0.20 to 0.75), probability (R-NR)> 0 = 0.89), 
it occurs faster (estimated tmax ∆(R-NR) -2.61 min (95% CrI -4.86 to -0.39), probability (R-
NR) > 0 = 0.01) and the estimated maximal value was greater than in non-responders 
(estimated Emax (R-NR) 0.28 L/min (95% CrI -0.20 to 0.74), probability (R-NR) >0 = 0.88). 
Importantly, the maximal effect was observed one minute after the end of the fluid 
infusion (1.16 minutes (95% CrI -0.56 to 2.84). In both groups, CO returns to base line 
similarly at 10 minutes time point. Patients with higher CO at baseline reach the maximal 
effect quicker regardless of the CO response group (Table 3). 
Mean systemic filling pressure analogue 
The estimated AUC is similar in both groups (estimated (R-NR) -1.52 mmHg (95% CrI -
8.8 to 5.5), probability (R-NR) >0 = 0.34), although the responders achieved the maximal 
effect quicker than non-responders. In non-responders there is no relationship between 
Pmsa baseline and AUC or dMax, but in responders there is a negative relationship so the 
higher Pmsa at baseline the smaller estimated AUC and smaller estimated dMax on Pmsa 
(Table 3, Figure 3 and 4). 
Central venous pressure 
The estimated AUC is greater in non-responders (estimated (R-NR) -4.91 mmHg (95% 
CrI -13.45 to 3.3), probability (R-NR) >0 = 0.12), although none of the other outcomes 
achieved a good level of evidence in terms of difference between groups.  
Those non-responders with higher CVP at baseline had a shorter time to observe the 
maximal value on CVP (Table 3, figure 5). In responders the increase in CVP at baseline 
increased the effect observed at 10 minutes time (Figure 6) 
Pharmacodynamics of a fluid challenge 13 
Heart rate (HR) 
The global effect was similar in both groups (estimated (R-NR) -3.71 bpm (95% CrI -
23.39 to 15.69) probability ∆(R-NR)>0 = 0.35), as well as the other outcomes. Patients 
with higher HR at baseline showed a decreased AUC in both groups (Table 3). DMax and 
d10 becomes greater (more negative) only in responders (Figure 7 and 8) as long as the 
baseline HR increases. 
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Discussion 
The main findings of this study are, first, the maximal change in CO is observed one 
minute after the end of fluid infusion; second, the global effect of the fluid challenge on 
CVP is higher in non-responders but not the change ten minutes after the end of the fluid 
infusion; third, the effect on CO generated by a single fluid challenge is dissipated over a 
ten minutes period similarly in both groups. 
Little is known about the pharmacodynamic effect of a fluid bolus of fluid. A 
pharmacokinetic/pharmacodynamic (PK/PD) model that could relate the PK behaviour 
with its observed therapeutic effect is complex, given the difficulties in measuring the 
“concentration” of the IV fluid bolus in blood samples. There are only a few studies 
published that describe the fluid PK in critically ill patients, as most describe the effects 
on less sick patients focusing on the changes in intra and extravascular volume with large 
amounts of fluid (25 ml·Kg-1)(26), or on fluid distribution across different fluid 
compartments (27) and also analysis of blood dilution as end-point of volume expansion 
(28). There are many studies (29-32) evaluating the haemodynamic effects of a fluid 
challenge between two time points (before and after the infusion). Recently, Nunes et al 
(33) reported an observational study in twenty patients with circulatory shock (14 septics) 
that received 500 ml of crystalloids over 30 minutes. The haemodynamics at 30 and 60 
minutes after the end of fluid infusion were reported. As in our study, the authors 
observed that MAP and cardiac filling pressures were similar between responders and 
non-responders over time points and, along with CO, all haemodynamics decrease 
towards baseline 30 minutes after the fluid infusion. The rate of fluid infusion is lower 
than in our study and the period observed is longer, which make us question if the results 
are purely related to the fluid bolus in septic patients, who are normally quite dynamic. 
Glassford et al (11) performed a systematic review of the effect of a fluid challenge in 
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septic patients, observing again a rapid dissipation of the haemodynamic effects. Our 
findings are in accordance with these studies although, to our knowledge, this is the first 
study assessing the immediate effect of a fluid challenge on the circulation using a PD 
approach and its interaction with baseline values and CO response in a cohort of 
postoperative patients. 
Overall effect of a fluid challenge: AUC 
The global effect of a fluid challenge is similar between responders and non-
responders for all tested haemodynamic variables except for CO and CVP. No difference 
was observed in MAP, which is in agreement with previous studies (29, 34-36). The 
arterial blood pressure is the result of the interaction between stroke volume and arterial 
elastance, and peripheral arterial pressure is also affected by pulse wave amplification 
(37, 38). AUC for CO was greater in responders, as expected, even when the maximal 
effect of the fluid challenge on CO does not happen immediately at the end of the fluid 
infusion, which is the most common value used to classify the groups (10). Actually, in 9 
(37.5 %) fluid challenges from “non-responders”, the maximal effect showed a further 
increase, achieving a change of CO greater than 10%. This may affect the results in other 
haemodynamic parameters, for example the CVP: while AUC is greater in non-responders 
none of the other outcomes achieved a level of evidence to support a clear difference 
between groups. The increase of CVP in non-responders is consistent with previous 
observations (39) and with the physiology of venous return: the flow is not increasing, 
the fluid is accumulated in the venous compartment, and the increase in CVP neutralises 
the increase of Pmsf (40). However, none of the other outcomes of CVP can be used to 
discriminate responders from non-responders. 
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The global effect of the fluid challenge on Pmsa was not different between groups, 
which is consistent with previous studies (22, 39). Pmsa is an analogue of Pmsf, which 
should increase after intravascular volume expansion, regardless of cardiac function.  
Interestingly, those patients with higher values of MAP, Pmsa or CVP (non-
responders) at baseline had smaller AUC respectively: this suggests that higher pressures 
do not necessarily mean lower compliance. Stress-relaxation in response to an increase in 
blood volume may increase vascular capacitance and reduce the global impact of the 
fluid challenge in the circulation, and this may be particularly evident when baseline 
pressures are already high enough. 
Maximum effect size: dmax 
The maximum effect size is similar between both groups for all the haemodynamics 
except for CO, which it is greater in responders. Even though the probability did not 
achieve clinical significance, our data suggest that HR decreases more in responders and 
CVP increases more in non-responders, although these estimated differences are very 
small. The probability that dmax in MAP was higher in non-responders is also close to a 
value of statistical relevance, however, the difference is so small (2.8 mmHg) that it 
would not be clinically relevant. Similar results were observed with CVP, the mean 
estimated difference between the two groups was -0.5 mmHg, which is again not 
clinically relevant. This emphasizes the importance of using flow-related variables to 
assess the response to a fluid challenge.  
The correlations between dMax and baseline values suggest that the CO response 
plays as a moderator in the case of MAP, Pmsa and HR: the higher baseline levels of MAP, 
Pmsa and HR in responders, the smaller is the dMax observed, while in non-responders 
baseline does not affect the dMax values. In the case of HR, this suggests that a fluid 
challenge can reduce the HR only in responders that are actually tachycardic. For MAP 
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(and Pmsa) a possible explanation is the afterload effect on the left ventricle, so that the 
higher the MAP, the more difficult it is to drive the arterial pressure up, even when flow is 
still increasing. 
Time to maximal effect 
The time of maximal effect was different between groups for MAP, CO and Pmsa. 
Interestingly, the maximal effect on MAP and CO in responders was estimated at almost 2 
and 1 minutes after the end of the fluid challenge respectively. During a bolus of IV fluids, 
part of the volume probably accumulates in the big veins and right atrium, and insofar as 
the end-diastolic ventricular volume is increasing, this volume is ejected into the systemic 
circulation. One potential cause of this delayed time is the presence of ventricular 
impairment or valve disease. Echocardiographic reports showed that most of our 
patients had normal ventricular size and function and only 6 – 7 % had valve disease (Table 
1). Another explanation would be the activation of mechanisms implicated in the intrinsic 
inotropy of myocardial cells such as release of angiotensin II, endothelin, activation of the 
mineralocorticoid receptor, transactivation of the epidermal growth factor receptor and 
others (41). Even though this mechanism may take a little bit longer than 1 or 2 minutes to 
be fully activated, they might contribute to the increase of CO and MAP after the end of 
the fluid challenge. 
In previous studies about fluid responsiveness, only 52 % of authors assessed the 
effect of the fluid challenge immediately after the fluid infusion, 21% did it between 1 and 
10 minutes, while the rest of the authors reported the assessment time at 12, 30, or even 
47 minutes after the fluid infusion (10). Glassford et al (11) reported that 10 of 19 studies 
assessed the haemodynamic effects immediately after the fluid infusion, 5 observed that 
effect 30 minutes after the fluid challenge and 3 studies reported the effect at 60 minutes 
time. Our findings suggest that, in order to avoid misclassifications regarding fluid 
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responsiveness, the effect of a fluid challenge on CO should be observed one minute 
after the end of the fluid infusion. 
Interestingly, in those responders with higher MAP at baseline the maximal effect on 
MAP would be less intense but quicker, and in those patients with higher values of CO at 
baseline, the maximal effect on CO would be quicker. In non-responders, the maximum 
value can also be observed quicker in those patients with higher CVP at baseline, which 
make sense because a quicker rise of CVP would be expected when CVP at baseline is 
high in non-responders 
Change from baseline after 10 minutes 
After ten minutes all the haemodynamics variables tend to return to baseline similarly 
in both groups. Although there is a high probability that CVP remains slightly higher in 
non-responders, it did not achieve enough level of evidence, and conclusions about fluid 
responsiveness cannot be drawn based on the changes after 10 minutes. This rapid 
dissipation of the effect of the fluid challenge could have several explanations: a) the 
stress-relaxation mechanism as described by Guyton (13), which consist on a progressive 
stretching of the vessel wall that allows the intravascular pressure to return back to 
baseline over a period of minutes after a large increase in pressure in response to a rapid 
increase in intravascular volume. This mechanism may certainly explain the progressive 
decrease of CO, MAP, CVP and Pmsa. (b) Redistribution of the volume infused from the 
central circulation to the rest of the cardiovascular system, and particularly to the 
compliant veins (spleen, liver, big abdominal veins and cutaneous venous plexus) (c) Part 
of the volume infused may leak out of the circulation by either capillary leak or diuresis, 
although in ten minutes this explanation seems unlikely. (d) A decrease in vascular 
smooth muscle tone caused by sympathetic inhibition may decrease the Pmsf. 
Sympathetic nerves innervating the vasculature display a tonic activity that sets a 
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background level of vasoconstriction. Decreasing sympathetic outflow below this tonic 
level causes vasodilation (42). It is known that in a short time scale (minutes – hours) the 
autonomic nervous system adjusts the circulation in keeping with behaviour, emotions 
and environment in order to meet the oxygen demand (43), so the influence of 
sympathetic-related vasodilation cannot be totally excluded. 
Clinical implications 
The fluid challenge technique, at least as described in this study, should be 
understood fundamentally as a diagnostic test for fluid responsiveness. This study 
demonstrates that a single fluid challenge does not change CO over a long period of time. 
Similar observations were made by Guyton(13), who used 30 – 50 ml/kg of three different 
fluids infused in 2 – 4 minutes in 36 mongrel dogs. Likewise, Glassford et al (11) shows 
that a fluid challenge in septic patients did not achieve any persisting haemodynamic 
effect. Nunes et al (33) also reported a transitory effect using 500 mL infused over 30 
minutes in septic patients. Importantly, stress-relaxation and redistribution of the 
intravascular volume between stressed and non-stressed volume are physiological 
mechanisms that allow adaptation to different intravascular volume status, so that they 
take place in hypovolaemic, euvolaemic and hypervolaemic states (44, 45). Regardless 
the baseline intravascular volume status, the transitory effect of a fluid challenge is also 
determined by the dose of fluids given: in this study the average dose would be 3.3 ml/kg, 
which is a lot less than the doses used in Guyton’s experiments where a slower decay 
effect was observed. Further research is needed to establish the minimal volume 
required to perform a fluid challenge that significantly change the Pmsf and test the 
circulation. 
Our results suggests some important clinical implications: a) as previously 
demonstrated (39) when a fluid challenge is performed using a rapid infusion rate and a 
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relatively “small” dose, its effect is sufficient to test if the patient is on the ascending part 
of the cardiac function curve , hence showing an increase in CO; b) the response to the 
fluid challenge is transitory, and as such also its clinical effect. Thus, our results emphasise 
that indications for further fluid therapy should not be made exclusively on the basis of 
the initial response to a fluid challenge as this may lead to fluid overload in some patients 
that transiently may increase their CO at every fluid challenge. Furthermore, fluid 
“unresponsiveness” should not be a clinical goal. Instead, optimal tissue perfusion should 
be the ultimate goal and must be evaluated before further fluids are given (44); c) the 
time when the response is assessed is an important factor when a clinician defines 
responders and non-responders. Likewise, when fluids are given with therapeutic 
purpose the assessment must take into account certain time for delayed compliance and 
volume redistribution, which could take at least ten minutes, depending on the dose 
given. It seems that the sustainability of haemodynamic changes depends on several 
factors such as the total volume of fluid given, the baseline haemodynamic values, the 
fluid redistribution rate and the baseline sympathetic tone. The effect of each particular 
factor will have to be evaluated in future studies.  
The main difference between a fluid challenge and “fluid resuscitation” is a matter of 
dose: a fluid challenge can tell the clinician if a particular patient may increase CO by 
giving fluids. If the patient remains under-filled following the first fluid challenge, it seems 
logical that the effect on CO and Pmsa would tend to dissipate and the patient may 
require further fluid challenges. However, it must be emphasised that “fluid 
responsiveness” is not equivalent to “fluid requirement”. In the context of fluid 
resuscitation, our results may suggest that continuous monitoring of CO and the use of 
additional interventions (vasoconstrictors) may be adequate in order to maintain CO, 
oxygen delivery and tissue perfusion over time. Similarly, protocols targeted to 
“maximisation” of the stroke volume might not necessarily represent an effective way of 
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maintaining a desired level of CO or MAP. The excess of volume in the circulation is 
compensated by redistribution between stress and non-stress volume, and in the worst 
cases, by a leak to interstitial space worsening tissue oxygenation. Further research is 
needed in order to find targets that can be used to guide fluid therapy regardless the 
fluid responsiveness status. 
Limitations 
There are several limitations in our study. First, the number of participants enrolled 
into the study is relatively small although comparable to other PD studies (46, 
47).However, the total number of fluid challenges observed, which is the total source of 
variability analysed, represents a reasonable sample size. By using a multilevel statistical 
model, multiple measurements per subject can be observed taking into account two 
levels of variability (within subject and between subjects). This approach overcomes the 
limitation of analysing simple measurements per subject in small samples.  
Secondly, many factors may affect the time-course effect of a fluid challenge on 
haemodynamics, so a reasonable question is if our findings can be extrapolated to a 
broader group of patients different from those in our sample. To answer this question we 
need to take into account a couple of considerations: first, the population of critically ill 
patients is very heterogeneous: vascular tone can vary considerably from post-operative 
to burned, from septics to trauma patients. To study the PD of a fluid challenge in such a 
heterogeneous population with a single mixed sample may result in invalid conclusions. 
We deliberately tried to select a relatively homogeneous group of participants (post-
operative high risk surgical patients), taking into account the most relevant co-factors in 
order to make a fairly clear description of the fluids effect. Therefore, our study can only 
be generalised to this group of patients; the second consideration is related to the nature 
of the intervention: as mentioned earlier, the fluid challenge is performed around the 
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glove in many different ways. Our study included only patients that received 250 ml of 
crystalloids (Hartmann’s solution) over five minutes. Logically, the type of fluid, the 
volume and the rate of infusion used could affect the haemodynamic response over time, 
so it would not be surprising to observe slightly different results with different 
techniques.  
That said, our observations are in line not only with the cardiovascular physiology but 
also with the limited evidence available in other critically ill patients (11, 33). Although 
those studies did not observed PD outcomes, they also highlight the transitory 
haemodynamic effect of the fluids in both responders and non-responders. Further 
prospective studies are required to describe the PD pattern in other subgroups of 
critically ill patients. 
Thirdly, the Pmsa is estimated using three measures: CVP, MAP and CO. Any 
inaccuracy in the measure of these variables has an impact on the value of Pmsa, in 
particular the CVP, so the results regarding Pmsa must be taken with caution. There are 
other methods described to measure Pmsf (22) in patients with intact circulation but they 
are technically difficult to implement for a continuous monitoring of Pmsf.  
Fourth, although all efforts were made to exclude patients with established severe 
cardiac failure, it was not possible to obtain echocardiographic information for all the 
patients given the observational nature of this study. In addition, our patients were in a 
steady haemodynamic state: this is a condition required to obtain good quality data and 
to link the changes observed to the intervention performed. It is possible to observe 
different results in severely hypovolaemic or unstable patients. Finally, since this project 
was conducted using a clinical protocol, objective data reflecting to what extent the 
protocol was followed is not available. 
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Conclusions 
The fluid challenge is an effective test for assessment of fluid responsiveness but its 
therapeutic effect on CO is dissipated in ten minutes. The maximal change on CO occurs 
at least over one minute after the end of the fluid infusion. The global effect of the fluid 
challenge on CVP is greater in non-responders, but not its change ten minutes after the 
fluid infusion. 
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Reference Legends 
 Figure 1 Relationship between mean arterial pressure at baseline and dMax (maximal change 
from baseline) observed and fitted and the interaction according to CO response: responders 
(Resp) and non-responders (Non Resp). 
 
Figure 2 Relationship between mean arterial pressure at baseline and tMax (time of maximal 
change from baseline) observed and fitted and the interaction according to CO response: 
responders (Resp) and non-responders (Non Resp). 
 
Figure 3 Relationship between mean systemic filling pressure analogue (Pmsa) at baseline 
and AUC (area under the curve) observed and fitted and the interaction according to CO 
response: responders (Resp) and non-responders (Non Resp). 
 
Figure 4 Relationship between mean systemic filling pressure analogue (Pmsa) at baseline 
and dMax (maximal change from baseline) observed and fitted and the interaction according to 
CO response: responders (Resp) and non-responders (Non Resp). 
 
Figure 5 Relationship between central venous pressure (CVP) at baseline and tMax (time 
ofmaximal change from baseline) observed and fitted and the interaction according to CO 
response: responders (Resp) and non-responders (Non Resp). 
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Figure 6 Relationship between central venous pressure (CVP) at baseline and d10 (change 
from baseline at ten minutes time) observed and fitted and the interaction according to CO 
response: responders (Resp) and non-responders (Non Resp). 
 
Figure 7 Relationship between heart rate (HR) at baseline and dMax (maximal change from 
baseline) observed and fitted and the interaction according to CO response: responders (Resp) 
and non-responders (Non Resp). 
 
Figure 8 Relationship between heart rate (HR) at baseline and d10 (change from baseline at 
ten minutes time) observed and fitted and the interaction according to CO response: responders 
(Resp) and non-responders (Non Resp). 
